Table 2 Uni- and multivariate analyses for OS

From: Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer

 

TS ( N =596)

VS ( N =508)

 

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

 

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Gender

F vs M

1.14 (0.92–1.42)

0.222

1.17 (0.95–1.46)

0.15

Age (cut-off: 65 years)

65 vs <65

1.67 (1.35–2.07)

0.0001

1.86 (1.38–2.49)

<0.0001

1.21 (0.98–1.49)

0.08

ECOG-PS

2 vs <2

2.12 (1.70–2.63)

0.0001

1.54 (1.14–2.07)

0.004

1.11 (0.83–1.47)

0.49

Synchronous metastases

yes vs no

1.31 (1.03–1.66)

0.026

1.05 (0.85–1.30)

0.66

Primary site

right vs left

1.52 (1.22–1.88)

0.0001

1.48 (1.18–1.86)

0.001

1.33 (1.05–1.69)

0.02

Primary resected

no vs yes

1.97 (1.53–2.53)

0.0001

2.27 (1.52–3.39)

<0.0001

1.11 (0.95–1.38)

0.23

Mucinous histology

yes vs no

1.38 (1.05–1.82)

0.018

1.43 (0.97–2.08)

0.065

1.26 (0.97–1.63)

0.09

Number of metastatic sites

>1 vs 1

2.08 (1.67–2.59)

0.0001

1.83 (1.38–2.43)

<0.0001

1.94 (1.56–2.42)

<0.0001

1.76 (1.38–2.25)

<0.0001

Peritoneal metastases

yes vs no

1.69 (1.31–2.18)

0.0001

1.37 (1.06–1.76)

0.01

Lung metastases

yes vs no

1.05 (0.82–1.35)

0.646

0.99 (0.74–1.21)

0.53

Distant lymph-node metastases

yes vs no

1.54 (1.18–2.02)

0.002

1.92 (1.50–2.47)

<0.0001

1.31 (0.99–1.74)

0.06

Tumour grading

3–4 vs 1–2

2.34 (1.83–3.01)

0.0001

1.23 (0.98–1.56)

0.08

RAS

mut vs wt

1.20 (0.97–1.49)

0.088

1.01 (0.82–1.25)

0.91

BRAF

mut vs wt

2.56 (1.84–3.56)

0.0001

2.98 (1.96–4.52)

<0.0001

2.72 (1.92–3.85)

<0.0001

2.33 (1.61–3.35)

<0.0001

  1. Abbreviations: CI=confidence intervals; HR=Hazard Ratio; N=number; OS=Overall Survival; PS=performance status; TS=training set; VS=validation set; wt=wild type.